

REVIEW

Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease

Leke Wiering,^{1,2} Pallavi Subramanian,³ and Linda Hammerich¹

¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hepatology and Gastroenterology, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany; ²Berlin Institute of Health at Charité – Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Junior Clinician Scientist Program, Berlin, Germany; and ³Institute for Clinical Chemistry and Laboratory Medicine, University Hospital and Faculty of Medicine, Technische Universität Dresden, Dresden, Germany

SUMMARY

Nonalcoholic fatty liver disease (NAFLD) frequently progresses to liver fibrosis, an important indicator of clinical outcomes. As hepatic stellate cell activation dictates fibrosis development during NAFLD, pathways that mediate hepatic stellate cell activation and inactivation ultimately determine course of disease in NAFLD.

Nonalcoholic fatty liver disease (NAFLD) is a fast growing, chronic liver disease affecting ~25% of the global population. Nonalcoholic fatty liver disease severity ranges from the less severe simple hepatic steatosis to the more advanced nonalcoholic steatohepatitis (NASH). The presence of NASH predisposes individuals to liver fibrosis, which can further progress to cirrhosis and hepatocellular carcinoma. This makes hepatic fibrosis an important indicator of clinical outcomes in patients with NASH. Hepatic stellate cell activation dictates fibrosis development during NASH. Here, we discuss recent advances in the analysis of the profibrogenic pathways and mediators of hepatic stellate cell activation and inactivation, which ultimately determine the course of disease in nonalcoholic fatty liver disease/NASH. (*Cell Mol Gastroenterol Hepatol* 2023;■:■-■; <https://doi.org/10.1016/j.jcmgh.2023.02.010>)

Keywords: Hepatic Stellate Cell; NAFLD; Fibrosis; NASH.

Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease worldwide with global prevalence rates of around 25% to nearly 30% in the adult population, which continue to increase.^{1,2} Because targeted therapies are still lacking, NAFLD represents a high burden for those affected and for health care systems around the world.^{3,4} NAFLD is considered the hepatic manifestation of the metabolic syndrome and is closely associated with diabetes mellitus, obesity, and dyslipidemia.⁵ NAFLD encompasses several liver pathologies ranging from simple hepatic lipid accumulation (hepatic steatosis) to the more severe nonalcoholic steatohepatitis (NASH).⁶ NASH is characterized by cellular stress, hepatocyte death, and inflammation, and may further progress to fibrosis, cirrhosis, and hepatocellular carcinoma.⁷ The transition to

fibrosis and cirrhosis is crucial because fibrosis is the key determinant of adverse outcomes and mortality and rates of liver-related complications increase with higher fibrosis stages.^{3,8} The impact of NASH as a health burden is demonstrated by the fact that NASH is the fastest growing cause of hepatocellular carcinoma in patients listed for liver transplantation in the United States.⁹ A key mechanism driving fibrosis development during NASH is the activation of hepatic stellate cells; once activated they differentiate into highly proliferative, extracellular matrix-producing myofibroblasts.¹⁰ Therefore, understanding the underlying mechanisms and pathways of hepatic stellate cell activation is fundamental for developing effective therapies for NAFLD/NASH. This review provides an overview of the pathologic functions of hepatic stellate cells in the context of NAFLD and discusses the mechanisms involved in their activation and deactivation, and therapeutic approaches targeting these mechanisms.

Role of Hepatic Stellate Cells in Nonalcoholic Fatty Liver Disease

Etiology of Nonalcoholic Fatty Liver Disease

NAFLD is an umbrella term encompassing various liver pathologies including simple hepatic steatosis or nonalcoholic fatty liver and the more advanced NASH.¹¹ The pathogenesis of NASH is multifactorial, resulting from numerous conditions acting in parallel, such as abnormal lipid metabolism, genetic predisposition, lipotoxicity, oxidative stress, gut dysbiosis, endoplasmic reticulum stress, mitochondrial

Abbreviations used in this paper: BAMBI, BMP and activin membrane-bound inhibitor; CCL2, chemokine (C-C motif) ligand 2; CCL3, chemokine (C-C motif) ligand 3; CCL5, chemokine (C-C motif) ligand 5; CCl₄, carbon tetrachloride; CTGF, connective tissue growth factor; EGF, epidermal growth factor; EP4, prostaglandin E2 receptor 4; GATA6, GATA-binding factor 6; GATA4, GATA-binding factor 4; IL, interleukin; MBOAT7, membrane-bound O-acyltransferase domain containing 7; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; PDGF, platelet-derived growth factor; PDGFR, platelet-derived growth factor receptor; PGE2, prostaglandin E2; PPAR, peroxisome proliferator activated receptor; TCF21, transcription factor 21; TGF, transforming growth factor; TNF, tumor necrosis factor.

© 2023 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

2352-345X

<https://doi.org/10.1016/j.jcmgh.2023.02.010>

dysfunction, and inflammation.^{11,12} NASH is associated with obesity and metabolic dysregulation, during which the adipose tissue exhibits low-grade inflammation and secretes adipokines and inflammatory cytokines, such as leptin, tumor necrosis factor (TNF), and interleukin (IL)6.¹³ Furthermore, hepatic lipid accumulation correlates with insulin resistance, endoplasmic reticulum stress, mitochondrial dysfunction, and reactive oxygen species generation.^{13,14} Additionally, NASH and NAFLD are associated with microbiota dysbiosis and a dysfunctional gut barrier resulting in an increased accumulation of gut-derived bacterial products, such as lipopolysaccharides and inflammation in the liver.^{13,15}

During NAFLD, various intrahepatic and extrahepatic triggers lead to activation of liver-resident immune cells and to recruitment of additional immune cells of the innate and adaptive immune systems.^{16,17} In particular, the liver resident macrophages named Kupffer cells play a major role in promoting inflammation during NAFLD.¹⁸ The activation of Kupffer cells leads to the secretion of proinflammatory chemokines and cytokines, such as chemokine (C-C motif) ligand 2 (CCL2), CCL3, CCL5, TNF- α and IL1 β , and IL6, which further aggravates inflammation by recruiting immune cells, such as monocyte-derived macrophages, neutrophils, and lymphocytes.¹⁹⁻²¹ Although inflammation is an important mechanism of pathogenesis, patients tend to be mostly asymptomatic with respect to their liver disease at the earlier stages of NAFLD because the incidence for clinical symptoms increases with fibrosis stages.³ This is in line with the findings that histopathologic inflammation alone is not a reliable predictor of NAFLD progression.²² Fibrosis severity is the critical indicator of mortality during NASH, with higher risk of liver-related complications and death in NASH patients with F3 or F4 stage fibrosis.^{3,23}

General Description of Hepatic Stellate Cells

Hepatic stellate cells are a nonparenchymal cell population, which represent the main fibrogenic cell type in the liver and account for approximately 5%–8% of all liver cells in the normal liver.^{24,25} Hepatic stellate cells are localized in the space of Disse, between the basolateral region of hepatocytes and the antiluminal surface of the sinusoidal endothelial cells.²⁶ In the healthy liver, the resting, quiescent hepatic stellate cells have several cytoplasmic processes that aid in making contact with the surrounding cells, such as endothelial cells and hepatocytes, and assist in the intercellular transport of cytokines and soluble mediators.²⁶ A distinct feature of quiescent hepatic stellate cells is the storage of retinoids (vitamin A and its metabolites) within their cytoplasmic lipid droplets.^{26,27} Under healthy conditions, approximately 80%–90% of the liver retinoids are stored in the lipid droplets of hepatic stellate cells.^{26,27}

There is extensive crosstalk between hepatic stellate cells and immune cells, such as macrophages.^{28,29} In vitro experiments using human macrophages and hepatic stellate cells show that soluble molecules derived from activated hepatic stellate cells induce the differentiation of macrophages to a proinflammatory phenotype.²⁸ Furthermore,

recent single-cell RNA sequencing data suggest that hepatic stellate cells communicate with their surrounding endothelial cells and immune cells by secreting a variety of soluble factors or “stellakines,” many of which are upregulated during NASH and liver injury. Thus, enhanced secretion of stellakines by hepatic stellate cells may be linked to NASH pathogenesis.²⁹

Activation of Hepatic Stellate Cells

Hepatic stellate cells can be activated by various stimuli during liver injury and NASH (Figure 1).³⁰ Hepatic stellate cells produce most myofibroblasts during liver injury, as shown in rodent models of liver fibrosis and NASH.^{25,31} The activation of quiescent hepatic stellate cells leads to their transdifferentiation into highly proliferative, extracellular matrix-producing activated hepatic stellate cells or myofibroblasts, with marked changes in their gene expression profile.^{10,32} These activated hepatic stellate cells exhibit a contractile, proliferative, and fibrogenic phenotype, which can be further distinguished from quiescent hepatic stellate cells by the loss of their retinol-containing lipid droplets.³³ Although such activation represents a useful mechanism in acute injury, sustained activation of hepatic stellate cells as seen in NASH results in an excess accumulation of extracellular matrix that ultimately leads to fibrosis.¹⁰ Activated hepatic stellate cells secrete a wide range of proinflammatory cytokines, such as CCL2, CCL5, IL8, chemokine (C-X-C motif) ligand-12 (CXCL12), and express adhesion molecules, such as intercellular adhesion molecule 1 and vascular cell adhesion molecule 1 and chemokine receptors (CCR5), resulting in increased recruitment and infiltration of immune cells into the liver.³⁴

Although quiescent hepatic stellate cells are rather homogeneous, activated hepatic stellate cells/myofibroblasts are much more heterogeneous.^{29,35} Single-cell RNA sequencing studies performed in mouse and human livers have identified distinct subsets of resting and activated hepatic stellate cells/myofibroblasts in fibrotic and cirrhotic livers.³⁵⁻³⁹ Functionally, quiescent hepatic stellate cells express high levels of growth factors and can protect hepatocytes from injury, whereas activated hepatic stellate cells mainly produce extracellular matrix proteins, such as different types of collagen I, but also collagen III, VI, and XIV, and cytokines and chemokines, promoting inflammation and fibrogenesis.^{29,39} Furthermore, activated hepatic stellate cells can also exhibit immunoregulatory effects: hepatic stellate cells from human livers can induce apoptosis of activated T cells via programmed cell death 1 ligand 1; influence B-cell activity via the same mechanism in mice; and exert a positive influence on tolerancing immune cells such as FoxP3⁺ regulatory T cells or myeloid-derived suppressor cells in different mouse models.⁴⁰⁻⁴³ Currently, it is not yet clear under which conditions hepatic stellate cells are proinflammatory and under which conditions they are tolerogenic. Several mechanisms trigger the activation of hepatic stellate cells during NAFLD pathogenesis, including metabolic injury with hepatocyte death and inflammation with activation and recruitment of diverse immune cells.³³




Figure 1. Pathways of hepatic stellate cell activation and survival during NAFLD. Various factors, such as lipid mediators, free cholesterol accumulation, oxLDL, palmitic acid, LPS, and immune cell-derived profibrotic molecules and growth factors, promote hepatic stellate cell activation and survival during NAFLD. OPN, osteopontin; HH ligands, hedgehog ligands; ROS, reactive oxygen species; GM-CSF, granulocyte macrophage colony-stimulating factor; LPS, lipopolysaccharide; TLR4, toll like receptor-4; SHH, sonic hedgehog; IHH, Indian hedgehog; NF- κ B, nuclear factor kappa-light-chain-enhancer of activated B cells; S1P, sphingosine-1-phosphate; oxLDL, oxidized low-density lipoprotein; LPA, lysophosphatidic acid; LPI, lysophosphatidylinositol; MSR1, macrophage scavenger receptor 1; miRNA, microRNA. Created with [Biorender.com](https://www.biorender.com).

The various triggers of hepatic stellate cell activation are described in detail in the later sections.

The activation of hepatic stellate cells is mainly mediated by growth factors, including transforming growth factor (TGF) β , platelet-derived growth factor (PDGF), and epidermal growth factor (EGF) (Figure 1). TGF β is the most potent activator of hepatic stellate cells and a key driver of fibrogenesis.¹⁰ Of note, TGF β levels are elevated in the serum of patients with NAFLD.^{44,45} In the context of NAFLD, TGF β originates mainly from immune cells, such as macrophages, and from activated hepatic stellate cells in a feed-forward loop.⁴⁶ During NAFLD, hepatocyte death and the resulting recruitment of macrophages is a critical driver of hepatic stellate cell activation and fibrosis via producing TGF β .¹⁰ When hepatocyte death occurs, recruited macrophages clear the apoptotic cells via the process of efferocytosis, which induces the production of immune regulatory factors, such as TGF β by macrophages, leading to the activation of hepatic stellate cells.^{10,47} Accordingly, inhibition of the TGF β pathway in a mouse model of NAFLD results in reduced activation of hepatic stellate cells and attenuates fibrosis, an effect that was most pronounced when IL13 was inhibited simultaneously.⁴⁸ Mechanistically, TGF β -induced hepatic stellate cell activation is mediated by the phosphorylation of SMAD proteins, such as SMAD 3, which ultimately leads to the upregulation of collagen I and

III synthesis by complexes of phosphorylated SMAD molecules acting as transcription factors.⁴⁹⁻⁵¹ Genes that are upregulated by SMAD also include α -smooth muscle actin (α -SMA) and connective tissue growth factor (CTGF).⁴⁶ Furthermore, TGF β can also induce activation of hepatic stellate cells in a SMAD-independent manner via mitogen-activated protein kinase-1, p38, and c-Jun N-terminal kinase mediated mechanisms, among others.^{52,53} In addition to these direct effects, latent TGF β can be deposited in the extracellular matrix and become subsequently activated by contraction of hepatic stellate cells through integrin- α V mediated mechanisms.^{54,55} Concordantly, inhibition of integrin- α V has antifibrotic effects during liver injury.^{54,55} Furthermore, the epigenetic regulator TET3 is involved in the TGF β /SMAD2/3 activation pathway, which can be inhibited by microRNA-488-5p in mice with liver fibrosis induced by CCl₄ treatment, high-fat diet, or bile duct ligation.⁵⁶ Moreover, CTGF, also known as *CCN2*, is 1 of the target genes of TGF β , which in addition to an increased secretion of extracellular matrix also promotes the proliferation and migration of hepatic stellate cells.⁵⁷ The expression of CTGF is relatively low in the healthy liver, but markedly increased in biopsies from patients with NAFLD.⁵⁸ Furthermore, silencing CTGF attenuates fibrosis development in a mouse model of CCl₄-induced liver injury.⁵⁹ In addition to TGF β -induced upregulation of CTGF, an

353 additional TGF β -independent upregulation via IL-13 has
354 been described.^{60,61}

355 PDGF is another profibrogenic growth factor. Under
356 physiological conditions, PDGF is mainly produced by
357 platelets; however, during liver injury PDGF is produced by
358 macrophages, injured endothelial cells, and activated hepatic
359 stellate cells.^{33,62} During liver injury, there is also an
360 increased expression of PDGF receptor- β (PDGFR β) in hepatic
361 stellate cells, which can promote increased signaling and
362 activation of hepatic stellate cells.⁶³ Accordingly, in
363 animal models of liver fibrosis, depletion of PDGFR β leads to
364 a reduction in fibrosis, conversely autoactivation of the receptor
365 increases fibrosis development.^{64,65} Moreover, PDGFR α is
366 increased in biopsies of patients with severe NAFLD, and levels
367 of circulating PDGFR β may help predict liver fibrosis.^{66,67} PDGF
368 signaling is mediated by dimerization and subsequent autophosphorylation
369 of the 2 PDGFRs after binding of a PDGF dimer.⁶⁸ PDGFRs are
370 receptor tyrosine kinases and on activation trigger subsequent
371 upregulation of mediators, such as phosphoinositide 3-kinase
372 and Janus kinase-1.⁶² Activation of PDGFR in hepatic stellate
373 cells promotes their proliferation and migration; promotes cell
374 survival; and increases the production of hedgehog pathway
375 ligands, such as sonic hedgehog, which have been proposed to
376 induce hepatic stellate cell activation.⁶⁹⁻⁷¹ Moreover, in
377 patients with NASH, hedgehog activity correlates with the
378 inflammation and fibrosis stage, whereas inhibition of
379 hedgehog signaling reduces fibrosis in a mouse model of
380 NASH.^{72,73} Moreover, vascular endothelial growth factor
381 has been shown to induce hepatic stellate cell activation and
382 proliferation, thereby leading to enhanced fibrosis development.
383 The EGF receptor also seems to be involved in profibrotic
384 pathways and is more strongly expressed in activated hepatic
385 stellate cells.⁷⁶ Inhibition of EGF signaling results in
386 decreased activation of hepatic stellate cells.^{76,77}

391 *Triggers of Hepatic Stellate Cell Activation in* 392 *Nonalcoholic Fatty Liver Disease*

393 *Lipotoxicity.* Hepatic lipotoxicity, caused by dysregulated
394 lipid metabolism and enhanced influx of free fatty acids from
395 peripheral tissues, is associated with NAFLD severity and
396 progression.⁷⁸ Several toxic lipids, such as fatty acids,
397 cholesterol, oxidized low-density lipoproteins, and others,
398 promote macrophage activation, upregulate their proinflammatory
399 phenotype, induce hepatic stellate cell activation (either
400 directly or indirectly via increased inflammation, Figure 1),
401 and promote NASH pathogenesis.⁷⁹⁻⁸² Free cholesterol is a
402 key lipotoxic molecule in the context of NASH.^{81,83} In
403 animal models of NAFLD, several studies have demonstrated
404 the importance of dietary cholesterol in promoting
405 inflammation, fibrosis, and NASH pathogenesis.⁸³⁻⁸⁵
406 Interestingly, dietary cholesterol and dietary fat act
407 synergistically to aggravate the metabolic features of
408 NASH in mice and trigger a hepatic pathology resembling
409 that of advanced NASH in humans, which is characterized
410 by increased macrophage recruitment, cholesterol
411 dysregulation, production of oxidized low-density

412 lipoproteins, and significant fibrosis.^{84,85} Furthermore, free
413 cholesterol is significantly increased in human NASH livers,
414 whereas only a mild nonsignificant increase is seen in NAFLD
415 samples.^{86,87} Remarkably, cholesterol crystals accumulate in
416 lipid droplets of steatotic hepatocytes, in mouse models of
417 high fat, high cholesterol diet-induced NASH, and in human
418 NASH, an event that is absent in samples with simple steatosis.
419 Steatotic, dead, or dying hepatocytes containing cholesterol
420 crystals are encircled by Kupffer cells/monocyte-derived
421 macrophages in an attempt to process the lipids, thereby
422 resulting in the formation of activated, lipid-laden foamy
423 macrophages and in the formation of the characteristic
424 “crown like structures.”^{81,88,89} In this context, the Kupffer
425 cells/monocyte-derived macrophages within the “crown like
426 structures” get activated by cholesterol crystals leading to
427 NLR family pyrin domain containing 3 (NLRP3) inflammasome
428 activation and the production of proinflammatory factors,
429 such as CCL2, IL1 β , and TGF β , which, along with amplifying
430 inflammation, also promote hepatic stellate cell activation.
431 Furthermore, accumulation of free cholesterol in hepatic
432 stellate cells leads to enhanced cell activation because of
433 sensitization of hepatic stellate cells to TGF β .⁹⁰ Free
434 cholesterol accumulation in hepatic stellate cells promotes
435 toll-like receptor-4 (TLR4) levels and signal transduction,
436 which results in the suppression of hepatic stellate cell-
437 specific BAMBI (a pseudoreceptor for TGF β) and consequently
438 TGF β -induced hepatic stellate cell activation is boosted.⁹⁰

440 In addition to directly activating hepatic stellate cells,
441 toxic lipids can also be indirect activators of hepatic stellate
442 cells, for instance via increasing inflammation. Lipid
443 accumulation in macrophages enhances their inflammatory
444 function.^{80,82,91,92} Specifically, accumulation of lipid
445 droplets in macrophages is important for the production of
446 proinflammatory molecules, such as prostaglandin E₂ (PGE₂),
447 IL1 β , and IL6.⁹¹ Fatty acids, such as palmitic acid, can
448 activate the TLR4-MD2 complex in macrophages to generate
449 reactive oxygen species and pro-IL1 β .⁹³ Additionally,
450 palmitic acid impairs autophagy in macrophages via activation
451 of hypoxia inducible factor-1 α ; the decreased autophagy
452 together with upregulation of the hypoxia inducible factor-
453 1 α pathway leads to enhanced inflammation through the
454 activation of nuclear factor- κ B and increased production of
455 CCL2 and IL1 β .⁹⁴ Uptake of oxidized low-density lipoproteins
456 by macrophages leads to lysosomal accumulation of these
457 lipids and to increased inflammation.⁸² In addition to
458 macrophages, oxidized low-density lipoproteins also promote
459 the activation of hepatic stellate cells, in cultured rat and
460 human cells.^{95,96} Oxidized low-density lipoprotein-induced
461 hepatic stellate cell activation is mediated by the scavenger
462 receptor CD36 (Figure 1).⁹⁶ Furthermore, in mouse
463 macrophages, the scavenger receptor “macrophage scavenger
464 receptor 1” (MSR1) facilitates palmitic acid-induced lipid
465 accumulation and enhances *Tnfa* and *Il6* mRNA expression.
466 The macrophage-derived cytokines, such as TNF α and IL1 β ,
467 in turn promote survival of activated hepatic stellate cells
468 or myofibroblasts, as shown by in vitro and in vivo
469 experiments.⁹⁷ Moreover, in a mouse model of NAFLD,
470 the PGE2/PGE2 receptor 4 (EP4) axis

promotes hepatic stellate cell activation and fibrosis via activating the extracellular signal-regulated kinase pathway and enhancing autophagy in hepatic stellate cells.⁹⁸

Although hepatocytes can accumulate cholesterol without necessary ballooning, this specific form of hepatocyte cell degeneration is an important histologic hallmark of NASH and is associated with fibrosis development.⁹⁹ Ballooned hepatocytes are profibrogenic and promote hepatic stellate cell activation possibly by producing sonic hedgehog.^{100,101} Furthermore, hedgehog signaling has been suggested to promote glycolysis in hepatic stellate cells thereby regulating the myofibroblast phenotype.¹⁰² Moreover, a direct link between NASH and hepatic cholesterol levels is well established.^{81,103} Cholesterol accumulation in hepatocytes leads to hepatic stellate cell activation and NASH by stabilizing the transcriptional regulator TAZ (also known as WWTR1) in hepatocytes, resulting in the secretion of the profibrotic factor Indian hedgehog.¹⁰⁴ Sonic hedgehog, Indian hedgehog, and TAZ are upregulated in human livers affected by NASH but not simple steatosis,^{105,106} suggesting a role of hepatocyte TAZ in promoting the transition from simple steatosis to NASH. Furthermore, fatty acids, such as palmitic acid, promote the release of extracellular vesicles from hepatocytes, which can be taken up by hepatic stellate cells resulting in their activation, both in human and mouse cells.¹⁰⁷ Hepatic stellate cells that internalize extracellular vesicles exhibit increased proliferation, chemotaxis, and enhanced expression of profibrotic genes, such as collagen, α -SMA, and tissue inhibitor of metalloproteinases-2.¹⁰⁷ Mechanistically, the extracellular vesicles contain microRNAs, such as miR-128-3p, and once transferred to the hepatic stellate cells, these microRNAs inhibit peroxisome proliferator activated receptor (PPAR) γ expression, ultimately leading to a switch from quiescent to activated hepatic stellate cell states.¹⁰⁷ Moreover, palmitate treatment of hepatocytes also results in the enhanced accumulation and secretion of the profibrotic lipid mediator, sphingosine-1-phosphate.¹⁰⁸ Of note, in addition to acting on hepatocytes, palmitic acid can also directly induce hepatic stellate cell activation via the inflammasome and possibly hedgehog signaling pathways.¹⁰⁹ Furthermore, steatotic hepatocytes upregulate Notch signaling, which correlates with NASH severity and results in the production of soluble mediators, such as osteopontin, which in turn activate hepatic stellate cells.^{110,111} Consistently, inhibition of Notch signaling in hepatocytes reduces liver fibrosis. Additionally, dying hepatocytes also release damage-associated molecular patterns, such as P2Y14 ligands and the alarmin IL33, which activate mouse and human hepatic stellate cells through direct and indirect mechanisms and thereby promote fibrogenesis.^{112,113}

Lipid Mediators. Profibrotic lipid mediators, such as lysophosphatidylinositol and lysophosphatidic acid, have been implicated in hepatic stellate cell activation and fibrogenesis (Figure 1).^{114,115} Inhibition of the major lysophosphatidic acid generating enzyme autotaxin (ectonucleotide pyrophosphatase/phosphodiesterase family member 2) using a selective inhibitor leads to significant improvement in fibrosis development in mouse models of

liver injury and NASH.¹¹⁶ Furthermore, autotaxin levels are elevated in the serum of patients with NAFLD and patients with liver cirrhosis as compared with healthy individuals and correlate with the stage of fibrosis.^{117,118} Furthermore, in a model of CCl₄-induced liver injury in rats, circulating levels of lysophosphatidic acid and autotaxin activity are increased and correlate with the extent of liver fibrosis.¹¹⁹ Moreover, circulating levels of lysophosphatidylinositol are increased in patients who have advanced fibrosis as compared with healthy individuals and the lysophosphatidylinositol-G protein-coupled receptor 55 axis has been shown to play a role in hepatic stellate cell activation.^{115,120} Interestingly, the occurrence of the *MBOAT7 rs641738C>T* risk variant (which reduces membrane-bound O-acyltransferase domain containing 7 [MBOAT7] mRNA and protein) is associated with increased hepatic lysophosphatidylinositol levels and accordingly with enhanced NASH fibrosis.^{121,122} Furthermore, even in the absence of the *MBOAT7 rs641738C>T* risk variant, obesity suppresses hepatic MBOAT7 levels.¹²⁰ Therefore, the increased production and secretion of lysophosphatidylinositol because of reduced MBOAT7 levels may promote hepatic stellate cell activation, although further studies are required to demonstrate the underlying mechanisms.

Furthermore, the sphingosine-1-phosphate axis is involved in hepatic stellate cell activation and hepatic fibrosis development.^{108,123-125} In cultured human hepatic stellate cells, sphingosine-1-phosphate treatment directly induces cell activation, as shown by the upregulation of α -SMA expression.¹⁰⁸ Furthermore, sphingosine-1-phosphate treatment also induces the migration of human hepatic myofibroblasts in culture.¹²⁴ Moreover, in rodent models of bile duct ligation- or CCl₄-induced liver injury, treatment with the sphingosine-1-phosphate receptor 1/3 antagonist or with an inhibitor of sphingosine kinase (an enzyme that generates sphingosine-1-phosphate) suppress liver injury and hepatic fibrosis.¹²³ In addition, in a mouse model of diet-induced NASH, treatment with an sphingosine-1-phosphate antagonist abrogates NASH development¹²⁵ with reduced ballooning, fibrosis, and inflammation following feeding with a diet high in fat, fructose, and cholesterol.¹²⁵ Moreover, palmitate treatment of hepatocytes results in the increased accumulation of intracellular and extracellular sphingosine-1-phosphate levels.¹⁰⁸ Interestingly, conditioned medium derived from palmitate-treated hepatocytes promotes activation of hepatic stellate cells in culture and this activation can be blocked by cotreatment with an sphingosine-1-phosphate receptor 1/3 antagonist; suggesting that palmitate-treated hepatocytes release extracellular sphingosine-1-phosphate that can function in a paracrine manner to activate hepatic stellate cells.¹⁰⁸ In addition to promoting hepatic stellate cell activation, sphingosine-1-phosphate can also directly act on immune cells, such as macrophages, to promote NASH pathogenesis.¹²⁶ In a rodent model of diet-induced NASH, genetic or pharmacologic inhibition of the sphingosine-1-phosphate receptor 4 significantly reduces inflammation and NASH fibrosis via mechanisms involving NLR family

pyrin domain containing 3 (NLRP3) inflammasome activation in macrophages.¹²⁶

Autophagy. Autophagy is a stress response mechanism that involves the degradation of cellular components and organelles through a lysosome-dependent pathway to generate energy and nutrients,³⁰ and plays a critical role in hepatic stellate cell activation and NASH fibrogenesis.^{30,33,98,127-129} Autophagy is required to sustain an activated phenotype in hepatic stellate cells.^{127,128} In culture-induced activation of mouse hepatic stellate cells a significant induction of autophagic flux is seen.¹²⁸ Moreover, treatment with an autophagy inhibitor reduces proliferation and expression of cellular activation markers, as shown in mouse and human hepatic stellate cells.¹²⁸ In mice containing autophagy defective hepatic stellate cells, CCl₄-induced liver injury results in abrogated extracellular matrix accumulation and fibrosis development.¹²⁷ Furthermore, the suppressed activation of hepatic stellate cells seen during autophagy deficiency can be partially rescued by the addition of exogenous fatty acids, such as oleic acid, therefore suggesting that the free fatty acids generated during autophagy are required to fuel cellular activation.¹²⁷ Several profibrotic/proinflammatory molecules, such as TGF β and lipopolysaccharides, are known to upregulate autophagy in hepatic stellate cells.^{129,130} TGF β induced autophagy plays a role in hepatic stellate cell activation, possibly via the c-Jun N-terminal kinase and extracellular signal-regulated kinase signaling pathways.¹²⁹ Moreover, lipopolysaccharide-induced upregulation of autophagy mediates the suppression of the TGF β pseudoreceptor BAMBI, thereby sensitizing hepatic stellate cells to TGF β -induced cell activation.¹³⁰ Furthermore, macrophage-derived PGE₂ can promote hepatic stellate cell activation and fibrosis by inducing autophagy.⁹⁸ In a mouse model of diet-induced NAFLD, M2-polarized macrophages induce hepatic stellate cell autophagy by producing PGE₂, which acts via its receptor EP4 on hepatic stellate cell, consequently enhancing hepatic stellate cell activation, extracellular matrix production, and fibrosis development.⁹⁸ Blocking the PGE₂/EP4 axis using an antagonist inhibits hepatic stellate cell autophagy and improves liver fibrosis.⁹⁸

Endoplasmic reticulum stress has been shown to be upstream of autophagy in the hepatic stellate cell activation cascade.^{30,131,132} In cultured hepatic stellate cells, overexpression of X-box binding protein 1, one of the unfolded protein response pathways, results in the upregulation of collagen expression; however, this induction of collagen is inhibited by deletion of an important autophagy mediator, autophagy related 7.¹³¹ These data suggest that the X-box binding protein 1-mediated pathway contributes to fibrogenic activation of hepatic stellate cells and is linked to autophagy. Moreover, inositol-requiring enzyme 1, another component of the unfolded protein response pathway, induces hepatic stellate cell activation and autophagy, mediated via the p38 mitogen-activated protein kinase pathway.¹³² Some of the key features of hepatic stellate cell activation are summarized in **Figure 1**.

Inflammation. During NAFLD, in addition to the metabolic triggers described previously, inflammation is a major

cause of hepatic stellate cell activation.^{10,33} Macrophages play a key role in the pathogenesis of NAFLD and are 1 of the cell types that interact with hepatic stellate cells.¹⁰ Proinflammatory/profibrotic macrophages send strong activation and survival signals to hepatic stellate cells via secreting cytokines, such as TGF β , PDGF, TNF- α , osteopontin, and IL1 β , among others (**Figure 1**).^{33,38,133} The chemokines CCL3 and CCL5 are also involved in hepatic stellate cell activation and fibrosis development during liver injury.^{20,21} In mouse models of liver fibrosis, induced by carbon tetrachloride (CCl₄) treatment or by feeding with a methionine and choline-deficient diet, blocking CCL3 or CCL5 results in decreased activation of hepatic stellate cells and reduced fibrosis development.^{20,21} Furthermore, in mouse and human tissues, single-cell RNA sequencing studies have identified the presence of a subset of macrophages that are TREM2⁺CD9⁺ and named as NASH-associated macrophages, lipid-associated macrophages, or scar-associated macrophages.^{29,38,134} These TREM2⁺CD9⁺ scar-associated macrophages are particularly abundant in injured and cirrhotic human livers and secrete high levels of cytokines and growth factors including, EGF and PDGF-BB, osteopontin, and IL1 β thereby providing a profibrogenic niche for hepatic stellate cells.³⁸ Furthermore, macrophages promote the survival of myofibroblasts via IL1 and TNF-dependent activation of the nuclear factor kappa-light-chain-enhancer of activated B cells pathway.⁹⁷ Moreover, the interaction between macrophages and hepatic stellate cells is not 1-sided; hepatic stellate cells also influence the differentiation of macrophages in the liver.¹³⁵ Activated hepatic stellate cells aggravate inflammation by inducing the proinflammatory polarization of macrophages via the p38 pathway and further promote the recruitment of monocyte-derived macrophages through secretion of CCL2.^{28,136}

In addition to macrophages, other immune cells also provide activation signals to hepatic stellate cells (**Figure 1**). Immunodeficient animals with severe combined immunodeficiency or B cell deficiency show lower activation of hepatic stellate cells during liver injury. Transfer of CD8⁺ T cells can reverse this effect.^{137,138} Furthermore, B cells can promote NAFLD pathogenesis and hepatic stellate cell activation by secreting TNF- α and IL6, as shown in a mouse model of diet-induced NAFLD.¹³⁹ Of note, hepatic stellate cell-derived retinoic acid has been shown to augment B-cell survival.¹⁴⁰ Moreover, CD8⁺ T cells are increased in different mouse models of NASH and in patients and can also have an activating effect on hepatic stellate cells through the secretion of profibrogenic cytokines, such as TNF α .^{141,142} However, certain subsets of CD8⁺ T cells have been shown to have an opposite effect, where CD69⁺CD103-CD8⁺ tissue resident memory T cells can induce apoptosis of activated hepatic stellate cells via the FasL-Fas pathway.¹⁴³ T helper type 17 cells induce hepatic stellate cell activation through the production of IL17 and IL22, which stimulate TGF β production in the liver and enhance TGF β signaling and production of extracellular matrix molecules by hepatic stellate cells.¹⁴⁴ Natural killer T cell-derived hedgehog ligands and osteopontin can activate hepatic stellate cells.¹⁴⁵ Genetic deletion of natural killer T

cells leads to a decrease in fibrogenic factors in methionine-choline-deficient diet fed mice.¹⁴⁵ Neutrophil granulocytes can also trigger activation of hepatic stellate cells via secretion of their typical granules (eg, via myeloperoxidase).¹⁴⁶ With respect to the neutrophil-hepatic stellate cell crosstalk a positive feedback loop has also been described, in which hepatic stellate cells once activated by neutrophil-derived reactive oxygen species in turn improve neutrophil survival by producing granulocyte-macrophage colony-stimulating factor and IL15, thereby amplifying inflammation and fibrosis.¹⁴⁷ Additionally, extrahepatic proinflammatory signals can act as triggers for hepatic stellate cell activation, because quiescent hepatic stellate cells express various receptors of the innate immune system including TLR4, which can be activated by lipopolysaccharides.¹⁴⁸ This is of particular relevance, because patients with NAFLD often show alterations of the gut-liver-axis with intestinal dysbiosis and increased translocation of intestinal bacteria.¹⁴⁹ Furthermore, it has been shown in mice that stimulation of quiescent hepatic stellate cells with lipopolysaccharides induces cell activation resulting in increased chemokine secretion, positively affecting chemotaxis of Kupffer cells/macrophages, and increasing the susceptibility to TGF β signaling through downregulation of the BMP and activin membrane-bound inhibitor (BAMBI; TGF β pseudoreceptor).¹⁵⁰ Although the most relevant aspect of TGF β signaling in the context of this review may be activation of hepatic stellate cells and therefore its profibrogenic role as described previously, it is also worth mentioning the interactions TGF β shows with various immune cells. TGF β has been described to promote the differentiation of FoxP3⁺CD4⁺ regulatory T cells, which was also associated with the progression of hepatocellular carcinoma.¹⁵¹ This immunosuppressive effect of TGF β seems to be mediated via retinoid metabolism by hepatic stellate cells.¹⁵² Because activated hepatic stellate cells lose their lipid droplets this may explain why this mechanism of liver-induced tolerance by TGF β is not sufficiently protective against inflammation in the presence of continuous stimuli as in NASH. TGF β can also promote a more anti-inflammatory/immunosuppressive phenotype in macrophages, sometimes called M2 or alternately activated macrophages.¹⁵³

Inactivation of Hepatic Stellate Cells During Nonalcoholic Fatty Liver Disease

Reversal of hepatic stellate cell activation has been demonstrated in rodent models of fibrosis resolution.^{154,155} During fibrosis regression activated hepatic stellate cells are removed either via apoptosis or by reverting to a quiescent-like phenotype (Figure 2), where they remain in a primed state and respond more rapidly to new fibrogenic stimuli, thereby contributing to faster fibrosis development on reinjury.¹⁵⁴⁻¹⁵⁶ Several transcription factors, such as PPAR γ , GATA-binding factor 6 (GATA6), GATA-binding factor 4 (GATA4), and transcription factor 21 (TCF21), have been implicated in regulating the deactivation of hepatic stellate cells.¹⁵⁷⁻¹⁵⁹ In a model of CCl₄-induced liver injury, mice




Figure 2. Inactivation of hepatic stellate cells during NAFLD. Activated hepatic stellate cells that accumulated during NASH fibrosis are removed during fibrosis resolution either by apoptosis or by reverting to an inactive phenotype. Additionally, activated hepatic stellate cells are removed by cell death induced by immune cells such as CD69⁺CD103⁺CD8⁺ T cells, $\gamma\delta$ T cells and NK cells. The transcription factors PPAR γ , GATA6, GATA4 and TCF21 play an important role in promoting and maintaining the inactivated phenotype of hepatic stellate cells. FasL, Fas ligand; HSC, hepatic stellate cells; NK, natural killer; TCF21, transcription factor 21. Created with [Biorender.com](https://www.biorender.com).

with hepatic stellate cell-specific deletion of GATA6 or PPAR γ are more susceptible to fibrosis development.¹⁵⁹ Moreover, regression of liver fibrosis is significantly reduced in hepatic stellate cell-specific GATA6-deficient mice and in hepatic stellate cell-specific PPAR γ -deficient mice as compared with wild-type mice, therefore suggesting that both GATA6 and PPAR γ are critical for maintaining the inactivated phenotype of hepatic stellate cells.¹⁵⁹ Furthermore, the expression of the transcription factor TCF21 is diminished in activated hepatic stellate cells of methionine and choline-deficient diet or CCl₄-treated fibrotic mouse livers as compared with normal livers.¹⁵⁸ This reduced TCF21 expression in hepatic stellate cells is restored during regression of liver fibrosis.¹⁵⁸ Overexpression of TCF21 in activated hepatic stellate cells/myofibroblasts downregulates the mRNA expression of profibrotic genes, such as *Colla1* (encoding for collagen, type I, alpha 1), *Pdgfrb* (encoding for PDGFR-beta), and *Acta2* (encoding for α -SMA); in contrast, the expression of hepatic stellate cell quiescence genes, such as *Gfap* (encoding for glial fibrillary acidic protein) and *Ngfr* (encoding for nerve growth factor

825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883**Table 1.** Clinical Trials With Antifibrotic Agents in Liver Fibrosis

Compound	Type	Phase	Trial number	Patients	Status	Treatment duration	Main result
Maraviroc	CCR-5 inhibitor	IV	NCT03129113	NAFLD and HIV	Completed	48 wk	No reduction of hepatic fat by MR-PDFF ¹⁶⁵
Belapectin	Galectin 3 inhibitor	IIb	NCT02462967	NASH F4 cirrhosis with portal hypertension	Completed	52 wk	No reduction of HPVG, no histologic improvement ¹⁷¹
Simtuzumab (GS-6624)	Monoclonal antibody against LOXL2	IIb	NCT01672866	NASH F3/4 fibrosis	Completed	96 wk	No histologic improvement of hepatic collagen ¹⁷⁵
Simtuzumab (GS-6624)	Monoclonal antibody against LOXL2	IIb	NCT01672879	NASH F4 cirrhosis	Completed	96 wk	No reduction of HPVG ¹⁷⁵
Pirfenidone	Antifibrotic agent	II	NCT02161952.	Chronic hepatitis C	Completed	24 mo	Significant histologic improvement ¹⁸¹
Pirfenidone	Antifibrotic agent	II	NCT04099407	Advanced fibrosis (mixed etiologies)	Completed	12 mo	Significant reduction of fibrosis by noninvasive measurement ¹⁸²
BMS-986263	HSP47 siRNA	II	NCT03420768	Hepatitis C F3/4 fibrosis	Completed	12 wk	Association with histologic improvement ¹⁷³
BMS-986263	HSP47 siRNA	II	NCT04267393	NASH compensated F4 cirrhosis	Recruiting		
PLN-1474	Integrin αVβ1 inhibitor	I	not available	NASH F3/4 fibrosis	Recruiting		

CCR-5, C-C chemokine receptor type 5; HPVG, hepatic venous pressure gradient; HSP47, Heat shock protein 47; LOXL2, Lysyl oxidase homolog 2; MR-PDFF, magnetic resonance proton density fat fraction; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis.

884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942

receptor), are upregulated.¹⁵⁸ Therefore, TCF21 acts as a deactivation factor in fibrogenic hepatic stellate cells. Furthermore, GATA4 is another transcription factor that is involved in the suppression of hepatic stellate cell activation.¹⁵⁷ Accordingly, overexpression of GATA4 in the liver promotes the regression of CCl₄-induced liver fibrosis.¹⁵⁷

Immune cells are also involved in suppressing hepatic stellate cell activity by inducing cell death (Figure 2).^{143,160} Specifically, $\gamma\delta$ T cells, certain CD8⁺ T cells, and natural killer cells can have a proapoptotic effect on hepatic stellate cells and thus an antifibrotic effect.^{143,160,161} Hepatic $\gamma\delta$ T cells induce apoptosis of hepatic stellate cells in a cell-to-cell contact-dependent mechanism and involving Fas-ligand, as shown in mouse models of liver injury.¹⁶⁰ Similarly, CD69⁺CD103⁺CD8⁺ tissue resident memory T cells promote apoptosis of activated hepatic stellate cells in Fas-ligand dependent fashion.¹⁴³ Moreover, natural killer cells also mediate an antifibrotic effect through inducing apoptosis of hepatic stellate cells.¹⁶² Activation of natural killer cells in mice with liver fibrosis attenuates fibrosis development by inducing cell death of activated hepatic stellate cells, whereas depletion of natural killer cells reverses this effect, a mechanism mediated by retinoic acid early inducible 1 and TNF.¹⁶¹

Targeting Hepatic Stellate Cells

Despite the increasing prevalence rates and intensive research, there is still no approved NASH-specific therapy available. The agents investigated in advanced clinical trials so far aim at improving metabolic injury (eg, PPAR agonists, farnesoid X receptor agonists, thymomimetics, glucagon-like peptide agonists and others), reducing hepatocyte injury (eg, ASK-1 inhibitors and caspase inhibitors) and inhibiting immune cell activation and recruitment (eg, CCR2/5 antagonists, PPAR agonists, farnesoid X receptor agonists). As described previously, these factors are important triggers for hepatic stellate cell activation, and pharmacologic manipulation of the upstream mediators or cells may lead to reduced activation of hepatic stellate cells. Specific effects on hepatic stellate cells have also been described for some of these substances; relevant clinical trials are summarized in Table 1. As mentioned, CCL5 is involved in the activation of hepatic stellate cells¹⁶³ and CCR-5 inhibitors, such as maraviroc, might therefore have antifibrotic effects. In vitro experiments with human hepatic stellate cells showed a reduction of collagen and extracellular matrix and TGF β as an important mediator of hepatic stellate cell activation.¹⁶⁴ However, clinical trials have only been conducted in a small cohort of patients with HIV with NAFLD, because maraviroc is already approved as a combination therapy in HIV treatment. In this study, no reduction in hepatic fat could be detected radiographically, but the applicability to other patient populations is uncertain.¹⁶⁵ Although PPAR agonists are thought to act primarily by influencing metabolism in hepatocytes, PPAR β , γ and δ are also expressed in hepatic stellate cells. Their effects in hepatic stellate cells are not yet comprehensively understood, but there is evidence that PPAR γ , for example, has inhibitory effects on

hepatic stellate cell activation and proliferation and can promote their inactivation.^{159,166,167} Reduced synthesis of extracellular matrix has also been described for glucagon-like peptide agonists, at least in NASH animal models.¹⁶⁸

In addition, substances with a more primary effect on hepatic stellate cells are also investigated. Galectin 3 is a cytosolic protein in cells of the innate immune system, especially in macrophages. Increased expression of galectin 3 causes activation of myofibroblasts and galectin 3 has profibrotic effects in various organs.¹⁶⁹ In animal studies, galectin 3 inhibitors have been shown to reduce fibrosis.¹⁷⁰ Belapectin is a pharmacologic inhibitor of galectin 3 that has been previously studied in clinical trials in patients with NASH. In a phase IIb study, no histologic improvement in fibrosis was achieved after 1 year.¹⁷¹ However, subgroup analysis showed improvement in hepatic stellate cells in patients without preexisting varices, and further studies are now ongoing for this subgroup. Another antifibrotic agent currently in clinical trials is BMS-986263, a nanoparticle containing HSP47 siRNA. HSP47 for its part is a serine proteinase inhibitor, a protein that specifically binds collagen as a so-called chaperone.¹⁷² Thus, by binding of the siRNA, collagen synthesis can be negatively affected. First results of the phase II study in patients with cured hepatitis C but advanced fibrosis (stage 3 or 4) were published in early 2022 and showed histologic improvement of fibrosis.¹⁷³ Currently, recruitment is underway for NCT04267393, a phase II study to test BMS-986263 in patients with NASH with compensated cirrhosis (F4). After synthesis, collagen is cross-linked by lysyl oxidases, resulting in greater stability. Therefore, another antifibrotic therapeutic approach is the inhibition of these enzymes. Simtuzumab is a monoclonal antibody against Lysyl Oxidase Like 2 (LOXL2), which prevents LOXL2-mediated stabilization of the extracellular matrix and was able to accelerate fibrosis resolution in mouse models.¹⁷⁴ However, in 2 phase IIb studies in patients with advanced NASH fibrosis and NASH cirrhosis, respectively, no significant effect was observed after 96 weeks of treatment.¹⁷⁵ It is possible that other lysyl oxidases may play a more relevant role.

Other fibrosis-specific therapeutic approaches are based on influencing TGF β . This can be activated in its latent form in an integrin-mediated manner, as already mentioned. Inhibition of integrin- α V by a pan α V inhibitor causes attenuation of fibrosis in various organ models including liver.^{176,177} Other integrin antibodies are already approved for different diseases (eg, vedolizumab for inflammatory bowel disease) and clinical trials are ongoing for idiopathic pulmonary fibrosis, but clinical trials in liver fibrosis are still lacking. Currently, only a phase I trial of the selective α V β 1 inhibitor PLN-1474 in patients with NASH has been announced.¹⁷⁸ Further interference with TGF β may be feasible with pirfenidone, an oral antifibrotic agent already approved for the treatment of idiopathic pulmonary fibrosis. The exact mechanism of action is not yet clear, but pre-clinical studies show reduced collagen synthesis and lower TGF β levels.^{179,180} A small clinical trial in patients with chronic hepatitis C showed histologic improvement in fibrosis and also reduced TGF β levels after 2 years of

1061 treatment.¹⁸¹ In the more recent PROMETEO study in pa-
 1062 tients with advanced fibrosis, of which the largest group
 1063 was NASH-related, a reduction in fibrosis was also seen, but
 1064 noninvasive measurement was used.¹⁸² Other growth me-
 1065 diators may also be modulated. Angiotensin receptor an-
 1066 tagonists are an established therapy option for
 1067 cardiovascular disease and there is some evidence from rat
 1068 models that these agents attenuate activation of hepatic
 1069 stellate cells.^{183,184} Angiotensin II has also been shown to
 1070 cause upregulation of CTGF and downstream activation of
 1071 SMAD2/3,¹⁸⁵ but human studies on the effect of these agents
 1072 in NAFLD are lacking. An ameliorating effect on the devel-
 1073 opment of NAFLD has also been described for EGF receptor.
 1074 In NAFLD mouse models, continuous administration of can-
 1075 certinib, an EGF receptor inhibitor, prevented the development
 1076 of steatosis. Additionally, in animals with preexisting NASH,
 1077 this therapy significantly reduced fibrosis.¹⁸⁶ Other studies
 1078 show a reduced number of activated hepatic stellate cells after
 1079 administration of an EGF receptor inhibitor in animal models
 1080 of progressive cirrhosis.⁷⁶ However, human studies on these
 1081 compounds are also lacking to date.

1082 Recently, obeticholic acid has been resubmitted to the
 1083 Food and Drug Administration for approval as the first
 1084 specific drug to treat NASH fibrosis.¹⁸⁷ However, specific
 1085 antifibrotic therapies are still lacking. It remains to be seen
 1086 how the new insights into hepatic stellate cells from single
 1087 cell analyses described previously can be translated into
 1088 therapeutic concepts.

1089 Conclusions and Future Perspectives

1090 The prevalence of NAFLD is growing rapidly, with
 1091 fibrosis severity as the critical determinant of disease pro-
 1092 gression and mortality. Hepatic stellate cells are the pre-
 1093 cursors for most profibrogenic, extracellular matrix
 1094 producing myofibroblasts during NAFLD. Various factors,
 1095 such as inflammation, lipotoxicity, lipid mediators, and
 1096 growth factors, can promote hepatic stellate cell activation
 1097 during NAFLD (Figure 1). Additionally, the recruitment and
 1098 activation of profibrogenic macrophages in response to he-
 1099 patocyte death is crucial for triggering hepatic stellate cell
 1100 activation and survival as outlined in the accompanying
 1101 review by Vonderlin and colleagues. In summary, recent
 1102 studies have expanded the knowledge on the pathways and
 1103 mechanisms of hepatic stellate cell activation and NASH
 1104 fibrosis. However, further studies are required to establish the
 1105 best intervention to inhibit and reverse the fibrogenic process.

1106 References

1107
 1108
 1109 1. Younossi ZM, Koenig AB, Abdelatif D, et al. Global
 1110 epidemiology of nonalcoholic fatty liver disease: meta-
 1111 analytic assessment of prevalence, incidence, and out-
 1112 comes. *Hepatology* 2016;64:73–84.
 1113 2. Le MH, Yeo YH, Li X, et al. Global NAFLD prevalence: a
 1114 systematic review and meta-analysis. *Clin Gastroenterol*
 1115 *Hepatol* 2019;2022(20):2809–2817.
 1116 3. Sanyal AJ, Van Natta ML, Clark J, et al. Prospective
 1117 study of outcomes in adults with nonalcoholic fatty liver
 1118 disease. *N Engl J Med* 2021;385:1559–1569.

1120 4. Younossi ZM, Blissett D, Blissett R, et al. The economic
 1121 and clinical burden of nonalcoholic fatty liver disease in
 1122 the United States and Europe. *Hepatology* 2016;
 1123 64:1577–1586.
 1124 5. Diehl AM, Day C. Cause, pathogenesis, and treatment of
 1125 nonalcoholic steatohepatitis. *N Engl J Med* 2017;
 1126 377:2063–2072.
 1127 6. Musso G, Cassader M, Gambino R. Non-alcoholic
 1128 steatohepatitis: emerging molecular targets and thera-
 1129 peutic strategies. *Nat Rev Drug Discov* 2016;
 1130 15:249–274.
 1131 7. Liu W, Baker RD, Bhatia T, et al. Pathogenesis of
 1132 nonalcoholic steatohepatitis. *Cell Mol Life Sci* 2016;
 1133 73:1969–1987.
 1134 8. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver
 1135 fibrosis, but no other histologic features, is associated
 1136 with long-term outcomes of patients with nonalcoholic
 1137 fatty liver disease. *Gastroenterology* 2015;149:
 1138 389–397.
 1139 9. Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic
 1140 steatohepatitis is the fastest growing cause of hepato-
 1141 cellular carcinoma in liver transplant candidates. *Clin*
 1142 *Gastroenterol Hepatol* 2019;17:748–755.
 1143 10. Schwabe RF, Tabas I, Pajvani UB. Mechanisms of
 1144 fibrosis development in nonalcoholic steatohepatitis.
 1145 *Gastroenterology* 2020;158:1913–1928.
 1146 11. Friedman SL, Neuschwander-Tetri BA, Rinella M, et al.
 1147 Mechanisms of NAFLD development and therapeutic
 1148 strategies. *Nat Med* 2018;24:908–922.
 1149 12. Caligiuri A, Gentilini A, Marra F. Molecular pathogenesis
 1150 of NASH. *Int J Mol Sci* 2016;17:1575.
 1151 13. Nati M, Chung KJ, Chavakis T. The role of innate im-
 1152 mune cells in nonalcoholic fatty liver disease. *J Innate*
 1153 *Immun* 2022;14:31–41.
 1154 14. Chakravarthy MV, Neuschwander-Tetri BA. The meta-
 1155 bolic basis of nonalcoholic steatohepatitis. *Endocrinol*
 1156 *Diabetes Metab* 2020;3:e00112.
 1157 15. Aron-Wisnewsky J, Vigliotti C, Witjes J, et al. Gut
 1158 microbiota and human NAFLD: disentangling microbial
 1159 signatures from metabolic disorders. *Nat Rev Gastro-*
 1160 *enterol Hepatol* 2020;17:279–297.
 1161 16. Cai J, Zhang XJ, Li H. The role of innate immune cells in
 1162 nonalcoholic steatohepatitis. *Hepatology* 2019;
 1163 70:1026–1037.
 1164 17. Sutti S, Albano E. Adaptive immunity: an emerging
 1165 player in the progression of NAFLD. *Nat Rev Gastro-*
 1166 *enterol Hepatol* 2020;17:81–92.
 1167 18. Kazankov K, Jorgensen SMD, Thomsen KL, et al. The
 1168 role of macrophages in nonalcoholic fatty liver disease
 1169 and nonalcoholic steatohepatitis. *Nat Rev Gastroenterol*
 1170 *Hepatol* 2019;16:145–159.
 1171 19. Krenkel O, Tacke F. Macrophages in nonalcoholic fatty
 1172 liver disease: a role model of pathogenic immunome-
 1173 tabolism. *Semin Liver Dis* 2017;37:189–197.
 1174 20. Heinrichs D, Berres ML, Nellen A, et al. The chemokine
 1175 CCL3 promotes experimental liver fibrosis in mice. *PLoS*
 1176 *One* 2013;8:e66106.
 1177 21. Berres ML, Koenen RR, Rueland A, et al. Antagonism of
 1178 the chemokine Ccl5 ameliorates experimental liver
 1179 fibrosis in mice. *J Clin Invest* 2010;120:4129–4140.

- 1179 22. Hagstrom H, Nasr P, Ekstedt M, et al. Fibrosis stage but
1180 not NASH predicts mortality and time to development of
1181 severe liver disease in biopsy-proven NAFLD. *J Hepatol*
1182 2017;67:1265–1273.
- 1183 23. Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V,
1184 et al. Fibrosis severity as a determinant of cause-specific
1185 mortality in patients with advanced nonalcoholic fatty
1186 liver disease: a multi-national cohort study. *Gastroenterology* 2018;155:443–457.
- 1187 24. Geerts A. History, heterogeneity, developmental biology,
1188 and functions of quiescent hepatic stellate cells. *Semin*
1189 *Liver Dis* 2001;21:311–335.
- 1190 25. Mederacke I, Hsu CC, Troeger JS, et al. Fate tracing
1191 reveals hepatic stellate cells as dominant contributors to
1192 liver fibrosis independent of its aetiology. *Nat Commun*
1193 2013;4:2823.
- 1194 26. Friedman SL. Hepatic stellate cells: protean, multifunc-
1195 tional, and enigmatic cells of the liver. *Physiol Rev* 2008;
1196 88:125–172.
- 1197 27. Sufletel RT, Melincovici CS, Gheban BA, et al. Hepatic
1198 stellate cells - from past till present: morphology, hu-
1199 man markers, human cell lines, behavior in normal and
1200 liver pathology. *Rom J Morphol Embryol* 2020;
1201 61:615–642.
- 1202 28. Chang J, Hisamatsu T, Shimamura K, et al. Activated
1203 hepatic stellate cells mediate the differentiation of mac-
1204 rophages. *Hepatol Res* 2013;43:658–669.
- 1205 29. Xiong X, Kuang H, Ansari S, et al. Landscape of inter-
1206 cellular crosstalk in healthy and NASH liver revealed by
1207 single-cell secretome gene analysis. *Mol Cell* 2019;
1208 75:644–660.
- 1209 30. Trivedi P, Wang S, Friedman SL. The power of plasticity-
1210 metabolic regulation of hepatic stellate cells. *Cell Metab*
1211 2021;33:242–257.
- 1212 31. Friedman SL, Roll FJ, Boyles J, et al. Hepatic lip-
1213 ocytes: the principal collagen-producing cells of
1214 normal rat liver. *Proc Natl Acad Sci U S A* 1985;
1215 82:8681–8685.
- 1216 32. Wang ZY, Keogh A, Waldt A, et al. Single-cell and bulk
1217 transcriptomics of the liver reveals potential targets of
1218 NASH with fibrosis. *Sci Rep* 2021;11:19396.
- 1219 33. Tsuchida T, Friedman SL. Mechanisms of hepatic stel-
1220 late cell activation. *Nat Rev Gastroenterol Hepatol* 2017;
1221 14:397–411.
- 1222 34. Carter JK, Friedman SL. Hepatic stellate cell-immune
1223 interactions in NASH. *Front Endocrinol (Lausanne)*
1224 2022;13:867940.
- 1225 35. Krenkel O, Hundertmark J, Ritz TP, et al. Single cell RNA
1226 sequencing identifies subsets of hepatic stellate cells
1227 and myofibroblasts in liver fibrosis. *Cells* 2019;8:503.
- 1228 36. Dobie R, Wilson-Kanamori JR, Henderson BEP, et al.
1229 Single-cell transcriptomics uncovers zonation of func-
1230 tion in the mesenchyme during liver fibrosis. *Cell Rep*
1231 2019;29:1832–1847.
- 1232 37. Rosenthal SB, Liu X, Ganguly S, et al. Heterogeneity of
1233 HSCs in a mouse model of NASH. *Hepatology* 2021;
1234 74:667–685.
- 1235 38. Ramachandran P, Dobie R, Wilson-Kanamori JR, et al.
1236 Resolving the fibrotic niche of human liver cirrhosis at
1237 single-cell level. *Nature* 2019;575:512–518.
39. Filliol A, Saito Y, Nair A, et al. Opposing roles of hepatic
1238 stellate cell subpopulations in hepatocarcinogenesis. *Nature*
1239 2022;610:356–3565.
- 1240 40. Charles R, Chou HS, Wang L, et al. Human hepatic
1241 stellate cells inhibit T-cell response through B7-H1
1242 pathway. *Transplantation* 2013;96:17–24.
- 1243 41. Li Y, Lu L, Qian S, et al. Hepatic stellate cells directly
1244 inhibit b cells via programmed death-ligand 1. *J Immunol*
1245 2016;196:1617–1625.
- 1246 42. Jiang G, Yang HR, Wang L, et al. Hepatic stellate cells
1247 preferentially expand allogeneic CD4+ CD25+ FoxP3+
1248 regulatory T cells in an IL-2-dependent manner. *Trans-
1249 plantation* 2008;86:1492–1502.
- 1250 43. Chou HS, Hsieh CC, Yang HR, et al. Hepatic stellate
1251 cells regulate immune response by way of induction of
1252 myeloid suppressor cells in mice. *Hepatology* 2011;
1253 53:1007–1019.
- 1254 44. Sepulveda-Flores RN, Vera-Cabrera L, Flores-
1255 Gutierrez JP, et al. Obesity-related non-alcoholic stea-
1256 tohepatitis and TGF-beta1 serum levels in relation to
1257 morbid obesity. *Ann Hepatol* 2002;1:36–39.
- 1258 45. Tarantino G, Conca P, Riccio A, et al. Enhanced serum
1259 concentrations of transforming growth factor-beta1 in
1260 simple fatty liver: is it really benign? *J Transl Med* 2008;
1261 6:72.
- 1262 46. Dewidar B, Meyer C, Dooley S, et al. TGF-beta in hepatic
1263 stellate cell activation and liver fibrogenesis-updated
1264 2019. *Cells* 2019;8:1419.
- 1265 47. Kourtzelis I, Hajishengallis G, Chavakis T. Phagocytosis
1266 of apoptotic cells in resolution of inflammation. *Front*
1267 *Immunol* 2020;11:553.
- 1268 48. Hart KM, Fabre T, Sciruba JC, et al. Type 2 immunity is
1269 protective in metabolic disease but exacerbates NAFLD
1270 collaboratively with TGF-beta. *Sci Transl Med* 2017;9:
1271 eaal3694.
- 1272 49. Furukawa F, Matsuzaki K, Mori S, et al. p38 MAPK
1273 mediates fibrogenic signal through Smad3 phosphory-
1274 lation in rat myofibroblasts. *Hepatology* 2003;
1275 38:879–889.
- 1276 50. Yoshida K, Matsuzaki K, Mori S, T, et al. Transforming
1277 growth factor-beta and platelet-derived growth factor
1278 signal via c-Jun N-terminal kinase-dependent Smad2/3
1279 phosphorylation in rat hepatic stellate cells after acute
1280 liver injury. *Am J Pathol* 2005;166:1029–1039.
- 1281 51. Breitkopf K, Godoy P, Ciucian L, et al. TGF-beta/Smad
1282 signaling in the injured liver. *Z Gastroenterol* 2006;
1283 44:57–66.
- 1284 52. Engel ME, McDonnell MA, Law BK, et al. Interdependent
1285 SMAD and JNK signaling in transforming growth factor-
1286 beta-mediated transcription. *J Biol Chem* 1999;
1287 274:37413–37420.
- 1288 53. Hanafusa H, Ninomiya-Tsuji J, Masuyama N, et al.
1289 Involvement of the p38 mitogen-activated protein kinase
1290 pathway in transforming growth factor-beta-induced
1291 gene expression. *J Biol Chem* 1999;274:27161–27167.
- 1292 54. Wipff PJ, Rifkin DB, Meister JJ, et al. Myofibroblast
1293 contraction activates latent TGF-beta1 from the extra-
1294 cellular matrix. *J Cell Biol* 2007;179:1311–1323.
- 1295 55. Annes JP, Chen Y, Munger JS, et al. Integrin alphaV-
1296 beta6-mediated activation of latent TGF-beta requires

- 1297 the latent TGF-beta binding protein-1. *J Cell Biol* 2004; 1298 165:723–734.
- 1299 56. Qiu J, Wu S, Wang P, et al. miR-488-5p mitigates hepatic stellate cell activation and hepatic fibrosis via suppressing TET3 expression. *Hepatol Int* 2022. 1300 1301
- 1302 57. Huang G, Brigstock DR. Regulation of hepatic stellate cells by connective tissue growth factor. *Front Biosci (Landmark Ed)* 2012;17:2495–2507. 1303 1304
- 1305 58. Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. *Hepatology* 2001;34(4 Pt 1):738–744. 1306 1307 1308 1309
- 1310 59. Hao C, Xie Y, Peng M, et al. Inhibition of connective tissue growth factor suppresses hepatic stellate cell activation in vitro and prevents liver fibrosis in vivo. *Clin Exp Med* 2014;14:141–150. 1311 1312 1313
- 1314 60. Sakai K, Jawaid S, Sasaki T, et al. Transforming growth factor-beta-independent role of connective tissue growth factor in the development of liver fibrosis. *Am J Pathol* 2014;184:2611–2617. 1315 1316 1317
- 1318 61. Liu Y, Meyer C, Muller A, et al. IL-13 induces connective tissue growth factor in rat hepatic stellate cells via TGF-beta-independent Smad signaling. *J Immunol* 2011; 1319 187:2814–2823. 1320 1321
- 1322 62. Ying HZ, Chen Q, Zhang WY, et al. PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics (Review). *Mol Med Rep* 2017;16:7879–7889. 1323 1324
- 1325 63. Wong L, Yamasaki G, Johnson RJ, et al. Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. *The J Clin Invest* 1994;94:1563–1569. 1326 1327 1328
- 1329 64. Czochra P, Klopčič B, Meyer E, et al. Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. *J Hepatol* 2006;45:419–428. 1330 1331
- 1332 65. Kocabayoglu P, Lade A, Lee YA, et al. beta-PDGF receptor expressed by hepatic stellate cells regulates fibrosis in murine liver injury, but not carcinogenesis. *J Hepatol* 2015;63:141–147. 1333 1334 1335
- 1336 66. Moylan CA, Pang H, Dellinger A, et al. Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. *Hepatology* 2014;59:471–482. 1337 1338 1339
- 1340 67. Lambrecht J, Verhulst S, Mannaerts I, et al. A PDGFRbeta-based score predicts significant liver fibrosis in patients with chronic alcohol abuse, NAFLD and viral liver disease. *EBioMedicine* 2019;43:501–512. 1341 1342 1343
- 1344 68. Heldin CH, Ertlund A, Rorsman C, et al. Dimerization of B-type platelet-derived growth factor receptors occurs after ligand binding and is closely associated with receptor kinase activation. *J Biol Chem* 1989; 1345 264:8905–8912. 1346 1347
- 1348 69. Yang L, Wang Y, Mao H, et al. Sonic hedgehog is an autocrine viability factor for myofibroblastic hepatic stellate cells. *J Hepatol* 2008;48:98–106. 1349 1350 1351
- 1352 70. Sicklick JK, Li YX, Choi SS, et al. Role for hedgehog signaling in hepatic stellate cell activation and viability. *Lab Invest* 2005;85:1368–1380. 1353 1354
- 1355 71. Kikuchi A, Pradhan-Sundt T, Singh S, et al. Platelet-derived growth factor receptor alpha contributes to human hepatic stellate cell proliferation and migration. *Am J Pathol* 2017;187:2273–2287. 1356 1357
72. Guy CD, Suzuki A, Zdanowicz M, et al. Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. *Hepatology* 2012;55:1711–1721. 1358 1359 1360 1361
73. Hirsova P, Ibrahim SH, Bronk SF, et al. Vismodegib suppresses TRAIL-mediated liver injury in a mouse model of nonalcoholic steatohepatitis. *PLoS One* 2013; 8:e70599. 1362 1363 1364 1365
74. Huang Y, Feng H, Kan T, et al. Bevacizumab attenuates hepatic fibrosis in rats by inhibiting activation of hepatic stellate cells. *PLoS One* 2013;8:e73492. 1366 1367 1368
75. Yang L, Kwon J, Popov Y, et al. Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. *Gastroenterology* 2014;146:1339–1350. 1369 1370 1371
76. Fuchs BC, Hoshida Y, Fujii T, et al. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. *Hepatology* 2014;59:1577–1590. 1372 1373 1374 1375
77. Qian Y, Han J, Zhou L, et al. Inhibition of epidermal growth factor receptor (EGFR) reduces lipopolysaccharide (LPS)-induced activation and inflammatory cytokines in hepatic stellate cells in vitro. *Med Sci Monit* 2018;24:5533–5541. 1376 1377 1378 1379
78. Rada P, Gonzalez-Rodriguez A, Garcia-Monzon C, et al. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? *Cell Death Dis* 2020;11:802. 1380 1381 1382 1383
79. Subramanian P, Hampe J, Tacke F, et al. Fibrogenic pathways in metabolic dysfunction associated fatty liver disease (MAFLD). *Int J Mol Sci* 2022;23:6996. 1384 1385 1386
80. Leroux A, Ferrere G, Godie V, et al. Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis. *J Hepatol* 2012;57:141–149. 1387 1388 1389 1390
81. Ioannou GN. The role of cholesterol in the pathogenesis of NASH. *Trends Endocrinol Metab* 2016;27:84–95. 1391 1392
82. Bieghs V, Walenbergh SM, Hendrikx T, et al. Trapping of oxidized LDL in lysosomes of Kupffer cells is a trigger for hepatic inflammation. *Liver Int* 2013;33:1056–1061. 1393 1394 1395
83. Van Rooyen DM, Larter CZ, Haigh WG, et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. *Gastroenterology* 2011;141:1393–1403. 1396 1397 1398 1399
84. Savard C, Tartaglione EV, Kuver R, et al. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. *Hepatology* 2013; 57:81–92. 1400 1401 1402
85. McGettigan B, McMahan R, Orlicky D, et al. Dietary lipids differentially shape nonalcoholic steatohepatitis progression and the transcriptome of Kupffer cells and infiltrating macrophages. *Hepatology* 2019;70:67–83. 1403 1404 1405 1406
86. Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalcoholic fatty liver disease. *Hepatology* 2007; 46:1081–1090. 1407 1408 1409
87. Caballero F, Fernandez A, De Lacy AM, et al. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. *J Hepatol* 2009;50:789–796. 1410 1411 1412
88. Ioannou GN, Haigh WG, Thorning D, et al. Hepatic cholesterol crystals and crown-like structures 1413 1414

- 1415 distinguish NASH from simple steatosis. *J Lipid Res* 2013;54:1326–1334. 1474
- 1416 89. Ioannou GN, Subramanian S, Chait A, et al. Cholesterol 1475
- 1417 crystallization within hepatocyte lipid droplets and its 1476
- 1418 role in murine NASH. *J Lipid Res* 2017;58:1067–1079. 1477
- 1419 90. Teratani T, Tomita K, Suzuki T, et al. A high-cholesterol 1478
- 1420 diet exacerbates liver fibrosis in mice via accumulation of 1479
- 1421 free cholesterol in hepatic stellate cells. *Gastroenterology* 2012;142:152–164. 1480
- 1422 91. Castoldi A, Monteiro LB, van Teijlingen Bakker N, et al. 1481
- 1423 Triacylglycerol synthesis enhances macrophage inflam- 1482
- 1424 matory function. *Nature Commun* 2020;11:4107. 1483
- 1425 92. Govaere O, Petersen SK, Martinez-Lopez N, et al. 1484
- 1426 Macrophage scavenger receptor 1 mediates lipid- 1485
- 1427 induced inflammation in non-alcoholic fatty liver dis- 1486
- 1428 ease. *J Hepatol* 2022;76:1001–1012. 1487
- 1429 93. Kim SY, Jeong JM, Kim SJ, et al. Pro-inflammatory hep- 1488
- 1430 atic macrophages generate ROS through NADPH oxi- 1489
- 1431 dase 2 via endocytosis of monomeric TLR4-MD2 1490
- 1432 complex. *Nature Commun* 2017;8:2247. 1491
- 1433 94. Wang X, de Carvalho Ribeiro M, Iracheta-Vellve A, et al. 1492
- 1434 Macrophage-specific hypoxia-inducible factor-1 α 1493
- 1435 contributes to impaired autophagic flux in nonalcoholic 1494
- 1436 steatohepatitis. *Hepatology* 2019;69:545–563. 1495
- 1437 95. Kang Q, Chen A. Curcumin eliminates oxidized LDL roles 1496
- 1438 in activating hepatic stellate cells by suppressing gene 1497
- 1439 expression of lectin-like oxidized LDL receptor-1. *Lab* 1498
- 1440 *Invest* 2009;89:1275–1290. 1499
- 1441 96. Schneiderhan W, Schmid-Kotsas A, Zhao J, et al. 1500
- 1442 Oxidized low-density lipoproteins bind to the scavenger 1501
- 1443 receptor, CD36, of hepatic stellate cells and stimulate 1502
- 1444 extracellular matrix synthesis. *Hepatology* 2001;34(4 Pt 1):729–737. 1503
- 1445 97. Pradere JP, Kluwe J, De Minicis S, et al. Hepatic mac- 1504
- 1446 rophages but not dendritic cells contribute to liver 1505
- 1447 fibrosis by promoting the survival of activated hepatic 1506
- 1448 stellate cells in mice. *Hepatology* 2013;58:1461–1473. 1507
- 1449 98. Cao Y, Mai W, Li R, et al. Macrophages evoke autophagy 1508
- 1450 of hepatic stellate cells to promote liver fibrosis in 1509
- 1451 NAFLD mice via the PGE2/EP4 pathway. *Cell Mol Life* 1510
- 1452 *Sci* 2022;79:303. 1511
- 1453 99. Kakisaka K, Suzuki Y, Fujiwara Y, et al. Evaluation of 1512
- 1454 ballooned hepatocytes as a risk factor for future pro- 1513
- 1455 gression of fibrosis in patients with non-alcoholic fatty 1514
- 1456 liver disease. *J Gastroenterol* 2018;53:1285–1291. 1515
- 1457 100. Rangwala F, Guy CD, Lu J, et al. Increased production of 1516
- 1458 sonic hedgehog by ballooned hepatocytes. *J Pathol* 1517
- 1459 2011;224:401–410. 1518
- 1460 101. Chung SI, Moon H, Ju HL, et al. Hepatic expression of 1519
- 1461 Sonic Hedgehog induces liver fibrosis and promotes 1520
- 1462 hepatocarcinogenesis in a transgenic mouse model. 1521
- 1463 *J Hepatol* 2016;64:618–627. 1522
- 1464 102. Chen Y, Choi SS, Michelotti GA, et al. Hedgehog con- 1523
- 1465 trols hepatic stellate cell fate by regulating metabolism. 1524
- 1466 *Gastroenterology* 2012;143:1319–1329. 1525
- 1467 103. Min HK, Kapoor A, Fuchs M, et al. Increased hepatic 1526
- 1468 synthesis and dysregulation of cholesterol metabolism is 1527
- 1469 associated with the severity of nonalcoholic fatty liver 1528
- 1470 disease. *Cell Metab* 2012;15:665–674. 1529
- 1471 104. Wang X, Cai B, Yang X, et al. Cholesterol stabilizes TAZ 1530
- 1472 in hepatocytes to promote experimental non-alcoholic 1531
- 1473 steatohepatitis. *Cell Metab* 2020;31:969–986. 1532
105. Wang X, Zheng Z, Caviglia JM, et al. Hepatocyte TAZ/ 1477
- WWTR1 promotes inflammation and fibrosis in nonal- 1478
- coholic steatohepatitis. *Cell Metab* 2016;24:848–862. 1479
106. Khajehahmadi Z, Mohagheghi S, Nikeghbalian S, et al. 1480
- Downregulation of hedgehog ligands in human simple 1481
- steatosis may protect against nonalcoholic steatohepa- 1482
- titis: is TAZ a crucial regulator? *IUBMB Life* 2019; 1483
- 71:1382–1390. 1484
107. Povero D, Panera N, Eguchi A, et al. Lipid-induced 1485
- hepatocyte-derived extracellular vesicles regulate hep- 1486
- atic stellate cell via microRNAs targeting PPAR- 1487
- gamma. *Cell Mol Gastroenterol Hepatol* 2015; 1488
- 1:646–663. 1489
108. Al Fadel F, Fayyaz S, Japtok L, et al. Involvement of 1490
- sphingosine 1-phosphate in palmitate-induced non- 1491
- alcoholic fatty liver disease. *Cell Physiol Biochem* 2016; 1492
- 40:1637–1645. 1493
109. Duan NN, Liu XJ, Wu J. Palmitic acid elicits hepatic 1494
- stellate cell activation through inflammasomes and 1495
- hedgehog signaling. *Life Sci* 2017;176:42–53. 1496
110. Zhu C, Kim K, Wang X, et al. Hepatocyte Notch activa- 1497
- tion induces liver fibrosis in nonalcoholic steatohepatitis. 1498
- Sci Transl Med* 2018;10:eaat0344. 1499
111. Yu J, Zhu C, Wang X, et al. Hepatocyte TLR4 triggers 1500
- inter-hepatocyte Jagged1/Notch signaling to determine 1501
- NASH-induced fibrosis. *Sci Transl Med* 2021;13: 1502
- eabe1692. 1503
112. Mederacke I, Filliol A, Affo S, et al. The purinergic P2Y14 1504
- receptor links hepatocyte death to hepatic stellate cell 1505
- activation and fibrogenesis in the liver. *Sci Transl Med* 1506
- 2022;14:eabe5795. 1507
113. McHedlidze T, Waldner M, Zopf S, et al. Interleukin-33- 1508
- dependent innate lymphoid cells mediate hepatic 1509
- fibrosis. *Immunity* 2013;39:357–371. 1510
114. Kaffe E, Katsifa A, Xylourgidis N, et al. Hepatocyte 1511
- autotaxin expression promotes liver fibrosis and cancer. 1512
- Hepatology* 2017;65:1369–1383. 1513
115. Fondevila MF, Fernandez U, Gonzalez-Rellan MJ, et al. 1514
- The L- α -Lysophosphatidylinositol/G protein- 1515
- coupled receptor 55 system induces the development 1516
- of nonalcoholic steatosis and steatohepatitis. *Hepatology* 1517
- 2021;73:606–624. 1518
116. Booijink R, Salgado-Polo F, Jamieson C, et al. A type IV 1519
- Autotaxin inhibitor ameliorates acute liver injury and 1520
- nonalcoholic steatohepatitis. *EMBO Mol Med* 2022;14: 1521
- e16333. 1522
117. Fujimori N, Umemura T, Kimura T, et al. Serum autotaxin 1523
- levels are correlated with hepatic fibrosis and ballooning 1524
- in patients with non-alcoholic fatty liver disease. *World J* 1525
- Gastroenterol* 2018;24:1239–1249. 1526
118. Pleri T, Martin D, Kronenberger B, et al. Serum autotaxin 1527
- is a parameter for the severity of liver cirrhosis and 1528
- overall survival in patients with liver cirrhosis: a pro- 1529
- spective cohort study. *PLoS One* 2014;9:e103532. 1530
119. Watanabe N, Ikeda H, Nakamura K, et al. Plasma lyso- 1531
- phosphatidic acid level and serum autotaxin activity are 1532

- increased in liver injury in rats in relation to its severity. *Life Sci* 2007;81:1009–1015.
120. Helsley RN, Venkateshwari V, Brown AL, et al. Obesity-linked suppression of membrane-bound O-Acyltransferase 7 (MBOAT7) drives non-alcoholic fatty liver disease. *eLife* 2019;8:e49882.
121. Mancina RM, Dongiovanni P, Petta S, et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. *Gastroenterology* 2016;150:1219–1230.
122. Thangapandi VR, Knittelfelder O, Brosch M, et al. Loss of hepatic Mboat7 leads to liver fibrosis. *Gut* 2021;70:940–950.
123. Yang L, Yue S, Liu X, et al. Sphingosine kinase/sphingosine 1-phosphate (S1P)/S1P receptor axis is involved in liver fibrosis-associated angiogenesis. *J Hepatol* 2013;59:114–123.
124. Li C, Zheng S, You H, et al. Sphingosine 1-phosphate (S1P)/S1P receptors are involved in human liver fibrosis by action on hepatic myofibroblasts motility. *J Hepatol* 2011;54:1205–1213.
125. Mauer AS, Hirsova P, Maiers JL, et al. Inhibition of sphingosine 1-phosphate signaling ameliorates murine nonalcoholic steatohepatitis. *Am J Physiol Gastrointest Liver Physiol* 2017;312:G300–G313.
126. Hong CH, Ko MS, Kim JH, et al. Sphingosine 1-phosphate receptor 4 promotes nonalcoholic steatohepatitis by activating NLRP3 inflammasome. *Cell Mol Gastroenterol Hepatol* 2022;13:925–947.
127. Hernandez-Gea V, Ghiassi-Nejad Z, Rozenfeld R, et al. Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. *Gastroenterology* 2012;142:938–946.
128. Thoen LF, Guimaraes EL, Dolle L, et al. A role for autophagy during hepatic stellate cell activation. *J Hepatol* 2011;55:1353–1360.
129. Zhang J, Jiang N, Ping J, et al. TGFbeta1 induced autophagy activates hepatic stellate cells via the ERK and JNK signaling pathways. *Int J Mol Med* 2021;47:256–266.
130. Chen M, Liu J, Yang W, et al. Lipopolysaccharide mediates hepatic stellate cell activation by regulating autophagy and retinoic acid signaling. *Autophagy* 2017;13:1813–1827.
131. Kim RS, Hasegawa D, Goossens N, et al. The XBP1 arm of the unfolded protein response induces fibrogenic activity in hepatic stellate cells through autophagy. *Sci Rep* 2016;6:39342.
132. Hernandez-Gea V, Hilscher M, Rozenfeld R, et al. Endoplasmic reticulum stress induces fibrogenic activity in hepatic stellate cells through autophagy. *J Hepatol* 2013;59:98–104.
133. Pastore M, Caligiuri A, Raggi C, et al. Macrophage MerTK promotes profibrogenic cross-talk with hepatic stellate cells via soluble mediators. *JHEP Rep* 2022;4:100444.
134. Daemen S, Gainullina A, Kalugotla G, et al. Dynamic shifts in the composition of resident and recruited macrophages influence tissue remodeling in NASH. *Cell Rep* 2021;34:108626.
135. Bonnardel J, T'Jonck W, Gaublomme D, et al. Stellate cells, hepatocytes, and endothelial cells imprint the Kupffer cell identity on monocytes colonizing the liver macrophage niche. *Immunity* 2019;51:638–654.
136. Xi S, Zheng X, Li X, et al. Activated hepatic stellate cells induce infiltration and formation of CD163(+) macrophages via CCL2/CCR2 pathway. *Front Med (Lausanne)* 2021;8:627927.
137. Novobrantseva TI, Majeau GR, Amatucci A, et al. Attenuated liver fibrosis in the absence of B cells. *J Clin Invest* 2005;115:3072–3082.
138. Safadi R, Ohta M, Alvarez CE, et al. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. *Gastroenterology* 2004;127:870–882.
139. Zhang F, Jiang WW, Li X, et al. Role of intrahepatic B cells in non-alcoholic fatty liver disease by secreting pro-inflammatory cytokines and regulating intrahepatic T cells. *J Dig Dis* 2016;17:464–474.
140. Thapa M, Chinnadurai R, Velazquez VM, et al. Liver fibrosis occurs through dysregulation of MyD88-dependent innate B-cell activity. *Hepatology* 2015;61:2067–2079.
141. Wolf MJ, Adili A, Piotrowitz K, et al. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. *Cancer Cell* 2014;26:549–564.
142. Bhattacharjee J, Kirby M, Softic S, et al. Hepatic natural killer T-cell and CD8+ T-cell signatures in mice with nonalcoholic steatohepatitis. *Hepatol Commun* 2017;1:299–310.
143. Koda Y, Teratani T, Chu PS, et al. CD8(+) tissue-resident memory T cells promote liver fibrosis resolution by inducing apoptosis of hepatic stellate cells. *Nat Commun* 2021;12:4474.
144. Fabre T, Molina MF, Soucy G, et al. Type 3 cytokines IL-17A and IL-22 drive TGF-beta-dependent liver fibrosis. *Sci Immunol* 2018;3:eaar7754.
145. Syn WK, Agboola KM, Swiderska M, et al. NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. *Gut* 2012;61:1323–1329.
146. Pulli B, Ali M, Iwamoto Y, et al. Myeloperoxidase-hepatocyte-stellate cell cross talk promotes hepatocyte injury and fibrosis in experimental nonalcoholic steatohepatitis. *Antioxid Redox Signal* 2015;23:1255–1269.
147. Zhou Z, Xu MJ, Cai Y, et al. Neutrophil-hepatic stellate cell interactions promote fibrosis in experimental steatohepatitis. *Cell Mol Gastroenterol Hepatol* 2018;5:399–413.
148. Bigorgne AE, John B, Ebrahimkhani MR, et al. TLR4-dependent secretion by hepatic stellate cells of the neutrophil-chemoattractant CXCL1 mediates liver response to gut microbiota. *PLoS One* 2016;11:e0151063.
149. Brandl K, Schnabl B. Intestinal microbiota and non-alcoholic steatohepatitis. *Curr Opin Gastroenterol* 2017;33:128–133.

- 1651 150. Seki E, De Minicis S, Osterreicher CH, et al. TLR4 en- 1710
 1652 hances TGF-beta signaling and hepatic fibrosis. *Nat* 1711
 1653 *Med* 2007;13:1324–1332. 1712
 1654 151. Shen Y, Wei Y, Wang Z, et al. TGF-beta regulates he- 1713
 1655 patocellular carcinoma progression by inducing Treg cell 1714
 1656 polarization. *Cell Physiol Biochem* 2015;35:1623–1632. 1715
 1657 152. Dunham RM, Thapa M, Velazquez VM, et al. Hepatic 1716
 1658 stellate cells preferentially induce Foxp3+ regulatory T 1717
 1659 cells by production of retinoic acid. *J Immunol* 2013; 1718
 1660 190:2009–2016. 1719
 1661 153. Chen B, Mu C, Zhang Z, et al. The love-hate relationship 1720
 1662 between TGF-beta signaling and the immune system 1721
 1663 during development and tumorigenesis. *Front Immunol* 1722
 1664 2022;13:891268. 1723
 1665 154. Troeger JS, Mederacke I, Gwak GY, et al. Deactivation of 1724
 1666 hepatic stellate cells during liver fibrosis resolution in 1725
 1667 mice. *Gastroenterology* 2012;143:1073–1083. 1726
 1668 155. Kisseleva T, Cong M, Paik Y, et al. Myofibroblasts revert 1727
 1669 to an inactive phenotype during regression of liver 1728
 1670 fibrosis. *Proc Natl Acad Sci U S A* 2012;109:9448–9453. 1729
 1671 156. Zisser A, Ipsen DH, Tveden-Nyborg P. Hepatic stellate 1730
 1672 cell activation and inactivation in NASH-fibrosis-roles as 1731
 1673 putative treatment targets? *Biomedicines* 2021;9:365. 1732
 1674 157. Arroyo N, Villamayor L, Diaz I, et al. GATA4 induces liver 1733
 1675 fibrosis regression by deactivating hepatic stellate cells. 1734
 1676 *JCI Insight* 2021;6. 1735
 1677 158. Nakano Y, Kamiya A, Sumiyoshi H, et al. A deactivation 1736
 1678 factor of fibrogenic hepatic stellate cells induces 1737
 1679 regression of liver fibrosis in mice. *Hepatology* 2020; 1738
 1680 71:1437–1452. 1739
 1681 159. Liu X, Xu J, Rosenthal S, et al. Identification of lineage- 1740
 1682 specific transcription factors that prevent activation of 1741
 1683 hepatic stellate cells and promote fibrosis resolution. 1742
 1684 *Gastroenterology* 2020;158:1728–1744. 1743
 1685 160. Hammerich L, Bangen JM, Govaere O, et al. Chemokine 1744
 1686 receptor CCR6-dependent accumulation of gammadelta 1745
 1687 T cells in injured liver restricts hepatic inflammation and 1746
 1688 fibrosis. *Hepatology* 2014;59:630–642. 1747
 1689 161. Radaeva S, Sun R, Jaruga B, et al. Natural killer cells 1748
 1690 ameliorate liver fibrosis by killing activated stellate cells 1749
 1691 in NKG2D-dependent and tumor necrosis factor-related 1750
 1692 apoptosis-inducing ligand-dependent manners. *Gastro-* 1751
 1693 *enterology* 2006;130:435–452. 1752
 1694 162. Melhem A, Muhanna N, Bishara A, et al. Anti-fibrotic 1753
 1695 activity of NK cells in experimental liver injury through 1754
 1696 killing of activated HSC. *J Hepatol* 2006;45:60–71. 1755
 1697 163. Seki E, De Minicis S, Gwak GY, et al. CCR1 and CCR5 1756
 1698 promote hepatic fibrosis in mice. *J Clin Invest* 2009; 1757
 1699 119:1858–1870. 1758
 1700 164. Coppola N, Perna A, Lucariello A, et al. Effects of 1759
 1701 treatment with Maraviroc a CCR5 inhibitor on a human 1760
 1702 hepatic stellate cell line. *J Cell Physiol* 2018; 1761
 1703 233:6224–6231. 1762
 1704 165. Mascolini M. Maraviroc or metformin does not lower liver 1763
 1705 fat in people with HIV and NAFLD. 18th European AIDS 1764
 1706 Conference. London, United Kingdom; 2021. 1765
 1707 166. Boyer-Diaz Z, Aristu-Zabalza P, Andres-Rozas M, et al. 1766
 1708 Pan-PPAR agonist lanifibranor improves portal hyper- 1767
 1709 tension and hepatic fibrosis in experimental advanced 1768
 1710 chronic liver disease. *J Hepatol* 2021;74:1188–1199. 1769
167. Staels B, Rubenstrunk A, Noel B, et al. Hepatoprotective 1710
 effects of the dual peroxisome proliferator-activated re- 1711
 ceptor alpha/delta agonist, GFT505, in rodent models of 1712
 nonalcoholic fatty liver disease/nonalcoholic steatohe- 1713
 patitis. *Hepatology* 2013;58:1941–1952. 1714
 168. Kim ER, Park JS, Kim JH, et al. A GLP-1/GLP-2 receptor 1715
 dual agonist to treat NASH: targeting the gut-liver axis 1716
 and microbiome. *Hepatology* 2022;75:1523–1538. 1717
 169. Slack RJ, Mills R, Mackinnon AC. The therapeutic po- 1718
 tential of galectin-3 inhibition in fibrotic disease. *Int J* 1719
Biochem Cell Biol 2021;130:105881. 1720
 170. Traber PG, Zomer E. Therapy of experimental NASH and 1721
 fibrosis with galectin inhibitors. *PLoS One* 2013;8:e83481. 1722
 171. Chalasani N, Abdelmalek MF, Garcia-Tsao G, et al. Effects 1723
 of belataceptin, an inhibitor of galectin-3, in patients with 1724
 nonalcoholic steatohepatitis with cirrhosis and portal hy- 1725
 pertension. *Gastroenterology* 2020;158:1334–1345. 1726
 172. Ito S, Nagata K. Roles of the endoplasmic reticulum- 1727
 resident, collagen-specific molecular chaperone Hsp47 1728
 in vertebrate cells and human disease. *J Biol Chem* 1729
 2019;294:2133–2141. 1730
 173. Lawitz EJ, Shevell DE, Tirucherai GS, et al. BMS-986263 1731
 in patients with advanced hepatic fibrosis: 36-week re- 1732
 sults from a randomized, placebo-controlled phase 2 1733
 trial. *Hepatology* 2022;75:912–923. 1734
 174. Ikenaga N, Peng ZW, Vaid KA, et al. Selective targeting 1735
 of lysyl oxidase-like 2 (LOXL2) suppresses hepatic 1736
 fibrosis progression and accelerates its reversal. *Gut* 1737
 2017;66:1697–1708. 1738
 175. Harrison SA, Abdelmalek MF, Caldwell S, et al. Simtu- 1739
 zumab is ineffective for patients with bridging fibrosis or 1740
 compensated cirrhosis caused by nonalcoholic steato- 1741
 hepatitis. *Gastroenterology* 2018;155:1140–1153. 1742
 176. Bouvet M, Claude O, Roux M, et al. Anti-integrin alpha(v) 1743
 therapy improves cardiac fibrosis after myocardial 1744
 infarction by blunting cardiac PW1(+) stromal cells. *Sci* 1745
Rep 2020;10:11404. 1746
 177. Henderson NC, Arnold TD, Katamura Y, et al. Targeting 1747
 of alphav integrin identifies a core molecular pathway 1748
 that regulates fibrosis in several organs. *Nat Med* 2013; 1749
 19:1617–1624. 1750
 178. Slack RJ, Macdonald SJF, Roper JA, et al. Emerging 1751
 therapeutic opportunities for integrin inhibitors. *Nat Rev* 1752
Drug Discov 2022;21:60–78. 1753
 179. Escutia-Gutierrez R, Rodriguez-Sanabria JS, Monraz- 1754
 Mendez CA, et al. Pirfenidone modifies hepatic miRNAs 1755
 expression in a model of MAFLD/NASH. *Sci Rep* 2021; 1756
 11:11709. 1757
 180. Salah MM, Ashour AA, Abdelghany TM, et al. Pirfenidone 1758
 alleviates concanavalin A-induced liver fibrosis in mice. 1759
Life Sci 2019;239:116982. 1760
 181. Flores-Contreras L, Sandoval-Rodriguez AS, Mena- 1761
 Enriquez MG, et al. Treatment with pirfenidone for two 1762
 years decreases fibrosis, cytokine levels and enhances 1763
 CB2 gene expression in patients with chronic hepatitis 1764
 C. *BMC Gastroenterol* 2014;14:131. 1765
 182. Poo JL, Torre A, Aguilar-Ramirez JR, et al. Benefits of 1766
 prolonged-release pirfenidone plus standard of care 1767
 treatment in patients with advanced liver fibrosis: 1768
 PROMETEO study. *Hepatol Int* 2020;14:817–827. 1769

- 1769 183. Liu J, Gong H, Zhang ZT, et al. Effect of angiotensin II and
1770 angiotensin II type 1 receptor antagonist on the prolifera-
1771 tion, contraction and collagen synthesis in rat hepatic
1772 stellate cells. *Chin Med J (Engl)* 2008;121:161–165. 1798
- 1773 184. Hirose A, Ono M, Saibara T, et al. Angiotensin II type 1
1774 receptor blocker inhibits fibrosis in rat nonalcoholic
1775 steatohepatitis. *Hepatology* 2007;45:1375–1381. 1799
- 1776 185. Li A, Zhang J, Zhang X, et al. Angiotensin II induces
1777 connective tissue growth factor expression in human
1778 hepatic stellate cells by a transforming growth factor
1779 beta-independent mechanism. *Sci Rep* 2017;7:7841. 1800
- 1780 186. Bhushan B, Banerjee S, Paranjpe S, et al. Pharma-
1781 cologic inhibition of epidermal growth factor receptor
1782 suppresses nonalcoholic fatty liver disease in a mu-
1783 rine fast-food diet model. *Hepatology* 2019;
1784 70:1546–1563. 1801
- 1785 187. Intercept Pharmaceuticals I. Intercept Resubmits New
1786 Drug Application to U.S. FDA for Obeticholic Acid in
1787 Patients with Liver Fibrosis due to NASH. Morristown,
1788 New Jersey, U.S.; 2022. 1802
- 1789
1790
1791
1792
1793
1794
1795
1796
1797
-
- Correspondence** 1798
Address correspondence to: Linda Hammerich, PhD, Charité –
Universitätsmedizin Berlin, Department of Hepatology and Gastroenterology,
Campus Virchow-Klinikum and Campus Charité Mitte, Augustenburger Platz
1, 10585 Berlin, Germany. e-mail: Linda.hammerich@charite.de. 1800
- Acknowledgments** 1801
Leke Wiering is a participant in the BIH Charité Junior Clinician Scientist
Program funded by the Charité – Universitätsmedizin Berlin, and the Berlin
Institute of Health at Charité (BIH). 1802
- CRedit Authorship Contributions** 1803
Leke Wiering, MD (Conceptualization: Equal; Data curation: Equal;
Visualization: Lead; Writing – original draft: Equal; Writing – review & editing:
Equal) 1804
- Pallavi Subramanian, PhD (Conceptualization: Equal; Visualization:
Supporting; Writing – original draft: Equal; Writing – review & editing:
Supporting) 1805
- Linda Hammerich, PhD (Conceptualization: Equal; Visualization: Supporting;
Writing – original draft: Equal; Writing – review & editing: Lead) 1806
- Conflicts of interest** 1807
The authors disclose no conflicts. 1808
- Funding** 1809
This work was supported by the German Research Foundation (GRF1382,
SPP2306). 1810
- 1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826